Alopecia Areata | Treatment Algorithms: Claims Data Analysis | US | 2024
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed. Two JAK inhibitors—Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Litfulo (ritlecitinib)—are approved for severe AA. As the treatment landscape continues to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in AA and to define the market niche for emerging products.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
- How has Olumiant been integrated into the treatment algorithm, and what is its source of business?
- What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Litfulo, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
